Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Emory University
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Jazz Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
Milton S. Hershey Medical Center
Mayo Clinic
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
Rush University Medical Center
Bristol-Myers Squibb
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Lumos Pharma
Emory University
Massachusetts General Hospital
Washington University School of Medicine
University of California, San Francisco
University of Washington
Medical College of Wisconsin
Pediatric Brain Tumor Consortium
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Radiation Therapy Oncology Group
Wake Forest University Health Sciences